GenomeWeb Article Offers Insight on GNS-Celgene Deal and Growing Demand for Causal Modeling
GNS Healthcare and Celgene have signed a service and license arrangement that allows the biopharma firm to use GNS Healthcare’s causal machine-learning and simulation platform for applications in drug discovery, clinical development, and commercialization and market access. Read the full story here.
Celgene Enters Into Service and License Arrangement for GNS Healthcare’s Causal Machine Learning Platform to Accelerate Value-Based and Precision Medicine Development
CAMBRIDGE, Mass. – November 29, 2016 – GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to massive and diverse data streams to better match drugs and other health interventions to individual patients, today announced that Celgene Corporation has entered into a service and license arrangement for the rights to […]